Work

Impact of expanding nirsevimab immunoprophylaxis, extended window and catch-up, on RSV hospitalizations in infants: a three-season, multicentre, population-based study in Emilia-Romagna, Italy

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Respiratory syncytial virus (RSV) is a major cause of hospitalization in infancy, particularly during the first months of life. Nirsevimab has substantially reduced RSV-related hospitalizations in early real-world studies, but the incremental population-level benefit of expanding an established seasonal programme to broader birth cohorts remains uncertain. In Emilia-Romagna, Italy, nirsevimab was introduced for the 2024–25 RSV season as seasonal at-birth immunoprophylaxis and expanded in 2025–26 to include at-birth immunoprophylaxis for infants born from August 2025 through March 2026 and catch-up immunization for infants born from April through July 2025. We assessed whether this expanded strategy provided an additional reduction in RSV-compatible hospitalizations. Methods We conducted a multicentre, population-based observational before–after study using hospital discharge records from eleven centres, covering approximately 69% of hospitalizations among infants aged <12 months. RSV-compatible hospitalizations were compared across three seasons: Pre-Nirsevimab (2023–24), Seasonal (2024–25), and Extended seasonal + catch-up (2025–26). Incidence rate ratios (IRRs) were estimated by negative binomial regression adjusted for sex and age. Net avoided hospitalizations were also calculated. Results Age-standardized RSV-compatible hospitalization rates declined from 21.9 per 100, 000 person-days in 2023–24 to 10.1 in 2024–25 and 7.8 in 2025–26. Compared with the Seasonal strategy, the Extended seasonal + catch-up strategy was associated with a further 22% reduction in hospitalization risk (IRR 0.78; 95% CI 0.69–0.88; p<0.001) and a 64% reduction versus Pre-Nirsevimab (IRR 0.36; 95% CI 0.31–0.42). An estimated 103.3 additional hospitalizations were avoided versus 2024–25 and 677.8 versus Pre-Nirsevimab, corresponding to approximately 52 and 339 avoided hospitalizations per 10, 000 infants, respectively. Findings were consistent in infants aged 0–180 days. Conclusions Expanding nirsevimab immunoprophylaxis was associated with a further significant reduction in RSV-compatible hospitalizations beyond that achieved with seasonal-only administration. Given the observational design, causal inference should remain cautious.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226008614
FWCI:
Cites: 21
Cited by:
Related to: 10
Parts: 2